403793-28-2

Basic information

• Product Name: 1-Bromo-4-(butane-1-sulfonyl)benzene
• Synonyms: 1-Bromo-4-(butane-1-sulfonyl)benzene;1-BroMo-4-(butylsulfonyl)benzene
• CAS NO: 403793-28-2
• Molecular Formula: C₁₀H₁₃BrO₂S
• Molecular Weight: 277.17802
• Mol File: 403793-28-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Bromo-4-(butane-1-sulfonyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-4-(butane-1-sulfonyl)benzene(403793-28-2)
• EPA Substance Registry System: 1-Bromo-4-(butane-1-sulfonyl)benzene(403793-28-2)

Safety Data

• Hazardous Substances Data: 403793-28-2(Hazardous Substances Data)

Usage

General Description

1-Bromo-4-(butane-1-sulfonyl)benzene is a chemical compound that consists of a benzene ring with a bromine atom at the 1 position and a butane-1-sulfonyl group at the 4 position. It is commonly used as an intermediate in organic synthesis, especially in the production of pharmaceuticals and agrochemicals. The butane-1-sulfonyl group, also known as a tosyl group, is a common protecting group in organic chemistry, and 1-Bromo-4-(butane-1-sulfonyl)benzene can be used to introduce this group into various organic molecules. It is also a versatile reagent in the preparation of a wide range of organic compounds. Additionally, 1-Bromo-4-(butane-1-sulfonyl)benzene is a clear, colorless to pale yellow liquid at room temperature with a characteristic odor, and it should be handled and stored with caution due to its potential hazards.

Upstream product

• 778-28-9 butyl para-toluenesulfonate 
• 106-53-6 para-bromobenzenethiol 
• 109-65-9 1-bromo-butane 
• 589-87-7 1,4-bromoiodobenzene 
• 16642-95-8 butanesulfinic acid sodium salt 
• 106-40-1 4-bromo-aniline 
• 121392-35-6 1-Bromo-4-butylsulphanylbenzene 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 53642-21-0 [4-(butane-1-sulfonyl)-phenyl]-hydrazine 

Relevant articles and documents

Visible-light-driven electron donor-acceptor complex induced sulfonylation of diazonium salts with sulfinates

This work reports an efficient sulfonylation reaction enabled by a visible-light-induced radical coupling reaction between phenyl/heterocyclic diazonium salts and sulfinates. Mechanistic experiments disclosed the formation of a versatile electron donor-acceptor (EDA) complex. This transformation is characterized by an easy operational procedure under mild conditions which avoids transition metals, ligands, catalysts, and oxidants.

Aryl alkyl sulfone compound and reducing coupling method for constructing sulfone compounds

The invention discloses an aryl alkyl sulfone compound shown as a formula (1) and a synthetic method thereof. The aryl alkyl sulfone compound is prepared by taking an aromatic iodide, an inorganic sulfur reagent and an alkyl bromide as reaction raw materials to carry out reacting in a solvent under action of alkali, a catalyst, a ligand, a reducing agent and an additive. According to the invention, an inorganic sulfur reagent is used as a sulfur source to construct the aryl alkyl sulfone compound in one step under catalysis and reduction conditions, so that the defect in synthesizing the arylalkyl sulfone compound by conventional oxidation of thioether is avoided. The aryl alkyl sulfone compound developed by the invention can be used for synthesizing aryl alkyl sulfone medicines.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

[1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: (I) These compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.